A Prospective Interventional Study on the Mechanism of Metformin Action Using Intestinal Mucosal Biopsy Tissue from Type 2 Diabetic Patients

Sakaguchi Kazuhiko0 个研究点目标入组 30 人开始时间: 2021年8月13日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•Metformin oral group
•1. patients scheduled to undergo lower gastrointestinal endoscopy
•2. patients with type 2 diabetes who have been taking metformin at least 1000 mg/day for more than 1 month
•3. patients who are expected to take no less than 1000 mg/day of metformin until they undergo lower gastrointestinal endoscopy
•4. patients aged 20 years or older but less than 75 years.
•5. patients who have given their written consent for the study.
•Metformin non-medication group
•1. patients scheduled to undergo lower gastrointestinal endoscopy
•2. patients with type 2 diabetes who have not taken metformin for more than 1 month.
•3. patients who are not expected to start metformin for a period of time before undergoing lower gastrointestinal endoscopy
•4. patients aged 20 years or older but less than 75 years.
•5. patients who have given their written consent for the study.

•1. pregnant women, lactating women, and women who may become pregnant.
•2. patients with inflammatory bowel disease (Crohn's disease, ulcerative colitis) or with a history of such disease.
•3. patients with a history of gastrointestinal tract surgery (excluding endoscopic mucosal resection)
•4. patients with suspected gastrointestinal tract infections
•5. patients with predisposition to bleeding (platelet abnormality: von Willebrand disease, coagulation abnormality: hemophilia, vascular abnormality: IgA) Vascular abnormalities: IgA vasculitis, etc.)
•6. patients taking two or more anticoagulants or antiplatelet agents
•7. patients suffering from dementia or psychiatric disease
•8. patients with HBV, HCV, or HIV.
•9. other patients who are judged to be inappropriate by the person in charge of this study.

发起方

Sakaguchi Kazuhiko